104P Development of a new generation of imatinib using structural biology techniques at ambient temperature

Abstract

Chronic myeloid leukemia (CML) is a kind of blood cancer and most CML patients have associated with a chromosomal anomaly with the BCR-ABL fusion oncogene, which occurs as a result of translocation between the Abelson murine leukemia (ABL1) gene on chromosome 9 and breakpoint cluster region (BCR) gene on chromosome 22. Imatinib mesylate is the first small molecule developed to target the BCR-ABL fusion protein. Imatinib reduces BCR-ABL activity by binding to the inactive conformation of tyrosine kinases.